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Background: It has been proposed that many hypersensitivity reactions to nanopharmaceuticals 
represent complement (C)-activation-related pseudoallergy (CARPA), and that pigs provide 
a sensitive animal model to study the phenomenon. However, a recent study suggested that 
pulmonary hypertension, the pivotal symptom of porcine CARPA, is not mediated by C in cases 
of polystyrene nanoparticle (PS-NP)-induced reactions.
Goals: To characterize PS-NPs and reexamine the contribution of CARPA to their pulmonary 
reactivity in pigs.
Study design: C activation by 200, 500, and 750 nm (diameter) PS-NPs and their opsonization 
were measured in human and pig sera, respectively, and correlated with hemodynamic effects 
of the same NPs in pigs in vivo.
Methods: Physicochemical characterization of PS-NPs included size, ζ-potential, cryo-
transmission electron microscopy, and hydrophobicity analyses. C activation in human serum 
was measured by ELISA and opsonization of PS-NPs in pig serum by Western blot and flow 
cytometry. Pulmonary vasoactivity of PS-NPs was quantified in the porcine CARPA model.
Results: PS-NPs are monodisperse, highly hydrophobic spheres with strong negative surface 
charge. In human serum, they caused size-dependent, significant rises in C3a, Bb, and sC5b-9, 
but not C4d. Exposure to pig serum led within minutes to deposition of C5b-9 and opsonic 
iC3b on the NPs, and opsonic iC3b fragments (C3dg, C3d) also appeared in serum. PS-NPs 
caused major hemodynamic changes in pigs, primarily pulmonary hypertension, on the same 
time scale (minutes) as iC3b fragmentation and opsonization proceeded. There was significant 
correlation between C activation by different PS-NPs in human serum and pulmonary hyper-
tension in pigs.
Conclusion: PS-NPs have extreme surface properties with no relevance to clinically used 
nanomedicines. They can activate C via the alternative pathway, entailing instantaneous 
opsonization of NPs in pig serum. Therefore, rather than being solely C-independent reactivity, 
the mechanism of PS-NP-induced hypersensitivity in pigs may involve C activation. These data 
are consistent with the “double-hit” concept of nanoparticle-induced hypersensitivity reactions 
involving both CARPA and C-independent pseudoallergy.
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Intravenous (IV) therapy with nanoparticle-based medicines 
(nanomedicines), as well as with many other biologics and 
nonbiological complex drugs and agents can cause hyper-
sensitivity reactions (HSRs), also known as “infusion” or 
“anaphylactoid” reactions. The rapidly arising symptoms, 
including but not limited to shortness of breath, facial redness 
and swelling, chest pain, back pain, flushing, rash, chills, 
panic and fever, are also typical of acute (type 1) allergy; 
however, a role for IgE has not been demonstrated in most 
of these reactions. As such, by basic immunology definition, 
these HSRs are “pseudoallergies”.
Based on the association of complement (C) activation 
with many of these adverse reactions, the term “complement-
activation-related pseudoallergy” (CARPA) was introduced1 
and with time increasingly considered as a clinically relevant 
concept in liposomal chemotherapy and other areas of IV 
pharmacotherapy,2–5 most recently in the medical use of 
nanoparticulate iron.6,7 Nevertheless, a recent review ques-
tioned the pseudoallergic nature of these HSRs, the role 
of C, and the use of pigs as a relevant model.8 The review 
concluded that “at present, current experimentally derived 
evidence is more in support of the rapid phagocytic response 
(RPR) hypothesis” (vs CARPA), essentially claiming that 
macrophage “bulimia” explains the HSRs independently of 
C activation. The assertion was not limited to the special case 
of polystyrene nanoparticle (PS-NP)-induced HSRs in pigs 
that an earlier study examined,9 but was proposed as a new 
theory of HSRs to compete with the CARPA concept.8
The experimental foundation of the RPR hypothesis was 
a joint international study involving pig experiments in our 
laboratory, wherein the animals were injected with PS-NPs of 
different shapes (spheres, rods, and disks), and the hemody-
namic changes they caused were correlated with C activation 
by these particles in pig blood in vitro. It was found that the 
strongest pulmonary hypertensive effect of spherical PS-NPs, 
taken as a measure of HSRs, correlated with the clearance 
of these particles from the blood of mice in vivo, as well as 
with their rapid uptake by cultured macrophages, but not 
with C activation in a whole-blood assay in vitro.9 The inhi-
bition of pulmonary reactivity by the macrophage inhibitor 
clodronate-containing liposomes was also taken as evidence 
of the causal role of macrophages in these reactions.9
While these data undoubtedly indicated a role of mac-
rophages in HSRs, their interpretation as evidence for the 
absence of a role of C was recently revisited and reassessed,10 
leading to the proposal that C activation could not be ruled 
out as a contributing mechanism of PS-NP-induced HSRs 
in pigs, at least on the basis of in vitro ELISA assays in pig 
whole blood.8 Here, we continued studying PS-NP-induced 




Carboxylated PS polybead microspheres (ie, PS-NPs) of 
200, 500, and 750 nm diameter were purchased from Poly-
sciences, Inc. (Warrington, PA, USA). The concentration 
(NPs/mL) was given by the manufacturer.11 A highly pure 
lipid mixture of hydrogenated soybean phosphatidylcholine 




) 3:1:1 w:w was purchased from Lipoid 
(Ludwigshafen, Germany). Rose bengal (RB) and disodium 
salt were purchased from Alfa Aesar (Haverhill, MA, USA). 
The antiporcine C5b-9 (C9 neoepitope [C9neo]) (AE11) anti-
body was obtained from Thermo Fisher Scientific (Waltham, 
MA, USA), and fluorescein isothiocyanate (FITC)-conju-
gated antihuman C3b/iC3b (7C12) from Dr Ronald Taylor 
(University of Pennsylvania). Studies have shown 7C12 to 
cross-react with pig C3b/iC3b. MicroVue ELISA kits for 
human C3a, sC5b-9, Bb, and C4d were obtained from Teco 
Medical (Sissach, Switzerland). Zymosan and EDTA were 
from Sigma-Aldrich Co. (St Louis, MO, USA).
Preparation of liposomes
PEGylated nanoliposomes with the lipid composition of 
HSPC–cholesterol–DSPE-PEG
2,000
 (3:1:1 w:w) were prepared 
as described previously.12,13 In short, lipids were dissolved 
in absolute ethanol at 62°C–65°C, followed by hydration by 
ultrapure water to form multilamellar vesicles. These were 
downsized to form small unilamellar vesicles by stepwise 
extrusion through polycarbonate membranes (Osmonics, 
Trevose, PA, USA) using a Lipex extruder (Transferra Nano-
sciences, Burnaby, BC, Canada) starting at a pore diameter 
of 400 nm and ending at a pore diameter of 100 nm.
Physicochemical analysis of Ps-NPs
Size and size distribution of PS-NPs were determined by 
dynamic light scattering.14 The ζ-potential was determined 
with a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) 
using sodium nitrate as electrolyte at 150 and 1.5 mM (high 
and low conductivity, respectively). Of note, sodium nitrate 
is much less destructive to electrodes than sodium chloride 
and has almost identical osmotic pressure and conductivity 
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contribution of carPa to polystyrene NP effects in pigs
of PS-NPs was analyzed by cryo-transmission electron 
microscopy (cryo-TEM).15 Surface hydrophobicity was 
assessed by measuring the adsorption of the xanthene dye Rose 
bengal (RB) to NPs as described earlier.16 Briefly, 0.04 mg/mL 
RB (final concentration) was incubated with PS-NPs at increas-
ing concentrations for 2 hours, followed by separation of NPs 
from the supernatant by ultracentrifugation at 155,000 g. Free 
RB was determined in the supernatant by reading OD
550
. 
For all these measurements, PEGylated (doxorubicin-free 
Doxil-like)13 nanoliposomes were used as reference. The 
surface area (SA) of PS-NPs and liposomes was calculated 
assuming that they were monodisperse, with diameter equal 
to the hydrodynamic diameter measured using dynamic light 
scattering. Total SA of PS-NPs was calculated according 
to the number of particles in each batch specified by the 
vendor,11 and for liposomes, it was measured with NanoSight 
tracking analysis (NanoSight NS300; Malvern Instruments).
Flow cytometry analysis of ic3b 
deposition and terminal complex (c5b-9) 
formation on Ps-NPs in pig serum 
in vitro
A mixture of 500 and 750 nm PS-NPs was incubated with 
pig serum (1:39 volume ratio) at 37°C in a heated shaker. 
Concentrations of beads were adjusted to present an equal 
surface of 0.3 cm2/mL serum. Aliquots were taken at 0, 1, 
3, 5, and 20 minutes, and C activation was terminated by 
adding an equal volume of ice-cold Dulbecco’s PBS (w/o 
Ca2+/Mg2+) containing 40 mM EDTA. PS-NPs incubated 
with serum for 20 minutes + 20 mM EDTA served as nega-
tive control for C activation. Subsequently, PS-NPs were 
pelleted by centrifugation (5,000 g for 6 minutes at 4°C), 
followed by washing twice in staining buffer (PBS–3% 
FBS–0.05% sodium azide). Particles were stained with anti-
iC3b-FITC antibody (7C12) or anti-C9neo antibody (aE11) 
for 30 minutes at 4°C. After washing, anti-C9neo-labeled 
particles were further processed for indirect staining with 
PE-labeled antimouse antibody (BioLegend, San Diego, CA, 
USA) in staining buffer for 30 minutes at 4°C. Zero-minute 
samples were also stained directly by PE-labeled secondary 
antibody without aE11 to get the fluorescence background 
of anti-C9neo. Antibody and bead concentrations were 
the same in each group. After washing, flow cytometry 
was performed by FACScan (Becton-Dickinson, Franklin 
Lakes, NJ, USA) using Kaluza software for data analysis. 
Beads were discriminated by their side scattering signals and 
were identified from a single particle gate identified by the 
shortest width of FL2. The arithmetic mean value of FL1 
(anti-iC3b-FITC staining) or FL2 (indirect anti-C9neo and 
secondary antibody-only staining) were identified for both 
bead populations. Preliminary studies showed no correlations 
between particle counts and fluorescence.
Detection of in vitro c activation by Ps-
NPs in pig serum by Western blot analysis
PS-NPs (diameters 200, 500, and 750 nm) were incubated 
with pig serum (Oriental Yeast, Tokyo, Japan) at 1:9 (v:v) for 
2–30 minutes (final concentration 145 cm2/mL) at 37°C. Then, 
the mixture was diluted with 0.1% sodium dodecyl sulfate 
(SDS) buffer and then subjected to separation on a 5%–20% 
SDS polyacrylamide-gel electrophoresis-gradient gel under 
reducing conditions and transferred electrophoretically onto 
Hybond ECL (GE Healthcare UK Ltd, Little Chalfont, UK). 
The membrane was blocked with PBS/0.05% Tween 20 and 
3% nonfat dry milk powder for 1 hour at room temperature. 
After three washes with PBS/0.05% Tween 20, membranes 
were incubated with anti-pig C3 antibody (rabbit polyclonal 
antibody, 1:1,000; LifeSpan Biosciences, Seattle, WA, USA) 
overnight at 4°C. After three washes, the membranes were 
incubated with HRP-conjugated anti-rabbit IgG (1:10,000; 
Thermo Fisher Scientific) for 1 hour at room temperature. After 
an additional three washes, the membranes were processed 
for enhanced chemiluminescence using ECL Plus chemilu-
minescence reagent (GE Healthcare UK Ltd). The obtained 
images were analyzed using an LAS-4000 EPUV mini and 
Multi Gauge version 3.2 (Fujifilm, Tokyo, Japan).
Detection of in vitro c activation by 
Ps-NPs in human serum by elIsa
Normal human sera from healthy volunteers were incubated 
PS-NPs (volume ratio 1:4) of 200, 500, and 750 nm diameter 
for 45 minutes at 37°C in a shaker. The NP number in each 
sample was adjusted to 72.5 mm2/mL, based on SA calcula-
tions. The reaction was terminated with the sample diluents 
of the ELISA kits supplemented with 10 mM EDTA. Mea-
surement of C3a, sC5b- sC5b-9, Bb, and C4d in the same 
samples was done with the respective ELISA kits by fol-
lowing the manufacturer’s instructions. OD was measured 
in a 96-well plate reader (FluoStar Omega, BMG Labtech, 
Ortenberg, Germany).
Monitoring of Ps-NP-induced 
hemodynamic changes in pigs
The details of pig experiments were the same as described 
earlier.1,9,17,18 In brief, mixed breed male Yorkshire–Hungarian 
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obtained from the Animal Breeding and Nutrition Research 
Institute (Budapest, Hungary). Animals were sedated with 
Calypsol/xylazine and then anesthetized with isoflurane 
(2%–3% in O
2
). Intubation was performed with endotracheal 
tubes to maintain free airways and enable controlled ventila-
tion if necessary. The animals were breathing spontaneously 
during the experiments. Surgery was done after povidone 
iodine (10%) disinfection of the skin. In order to measure 
pulmonary arterial pressure (PAP), a Swan–Ganz catheter 
(AI-07124, 5 Fr, 110 cm; Teleflex, Research Triangle Park, 
NC, USA) was introduced into the pulmonary artery via 
the right external jugular vein. Additional catheters were 
placed into the left femoral artery to record systemic arterial 
pressure, to the left external jugular vein for saline and 
drug administration, and to the left femoral vein for blood 
sampling. Heart rate was measured from electrocardiography 
signals, recorded through foam type Ag/AgCl monitoring 
electrodes (2228; 3M Health Care, Saint Paul, MN, USA). 
Blood pressure and heart rate signals were evaluated by 
LabChart Pro version 8 software (ADInstruments, Dunedin, 
New Zealand). All experiments were performed following 
national guidelines and regulations (40/2013. II. 14. govern-
ment decree on animal testing) and ethical and legal permits 
obtained from Semmelweis University’s Veterinary Health 
and Ethical Committee and the Metropolitan Veterinary and 
Food Chain Inspection Station in Budapest, Hungary.
Treatment of pigs with Ps-NPs
PS-NP test samples and zymosan were injected in the 
animals as bolus (,5 seconds) into the jugular vein, followed 
by a 5 mL wash with saline. Concentrations of different NPs 
in the stocks were adjusted to equal total SA, specified in 
the text.
statistical analyses
Statistical methods applied included paired and unpaired 
t-tests, one-way ANOVA followed by Tukey’s multiple 
comparison, linear regression, and correlation analyses, as 
specified in the text. These analyses were performed using 
GraphPad Prism software (GraphPad Software, La Jolla, 
CA, USA).
Results
Physicochemical features of Ps-NPs 
and liposomes
PS-NP dispersions and PEGylated liposomes were character-
ized for size, charge, morphology, and hydrophobicity. The 
results are shown in Table 1 and Figure 1A and B. Table 1 
shows that all PS-NP dispersions and liposomes had uni-
modal, relatively narrow size distribution. It is also seen in 
the table that PS-NPs had strong negative surface charge at 
both low and high ionic strength, wherein the former values 
were closer to the “real” electric surface potential of PS-NPs, 
while the latter reflected more the conditions in biological 
fluids, such as plasma.19 In contrast to PS-NPs, PEGylated 
liposomes displayed only slight negative (practically neutral) 
surface charge at high ionic strength.
Direct cryo-TEM imaging showed PS-NPs as dense 
black spheres with diameters corresponding to the vendor-
specified values of 200, 500, and 750 nm11 (Figure 1A–C). 
Unilamellar PEGylated nanoliposomes were visible as black 
rings (Figure 1D). Measuring the partition of RB between 
phospholipid membranes and the water phase has been used 
in pharmaceutical studies to determine the surface hydropho-
bicity of NP drug-delivery vehicles.16 The assay principle 
is that the level of dye adsorption per unit of SA is directly 
proportional to the surface hydrophobicity, and the higher 
the hydrophobicity, the higher the adsorption. As shown in 
Figure 1E, plotting of OD
550
 against total particle SA resulted 
in a logarithmic curve for 200 and 500 nm PS-NPs, while the 
750 nm PS-NPs adsorbed over 90% of the RB at very low 
concentration. PEGylated liposomes, on the other hand, did 
not adsorb the dye at all. Furthermore, the OD
550
/unit SA was 
proportional with NP size and reached a plateau, suggesting 





SPAN*** ZP* (mV) at 
low conductivity
ZP* (mV) at high 
conductivity
Particles/mL**
750 791±23.5 0.74±0.08 -56.1±0.81 -16.5±0.81 1.0811
500 545.1±6.3 0.70±0.03 -56.3±1.5 -32.8±3.15 3.6411
200 194.3±3.3 0.69±0.04 -43.5±0.81 -28.6±2.84 5.6812
Pegylated liposomes 132.3±1.3 0.83±0.02 -17.9±1.4 -3.6±0.67 9.0412
Notes: *Measured at low (1.5 mM NaNO3) and high (150 mM NaNO3) conductivity. **given by manufacturer. For liposomes, it was measured as described in the Materials 
and methods section. all values except for Particles/ml (ml) are means ± sD (n=3). ***sPaN =(d90-d10)/d50 – the larger the sPaN the larger the size distribution. d-values 
are the intercepts for 10%, 50% and 90% of the volume distribution.
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contribution of carPa to polystyrene NP effects in pigs
saturation of binding and particle geometry (curvature) 
having an inverse impact on adsorption. Possibly, the lower 
curvature with flatter surface plane favored the binding of 
RB. In conclusion, PS-NPs showed significant differences 
from PEGylated liposomes in surface charge, hydrophobic-
ity, and internal content. Moreover, hydrophobicity depended 
on NP size, with absolute values increasing in the order 
200,500,750 nm diameter.
complement activation by Ps-NPs in 
pig serum: flow cytometry evidence of 
terminal complex and c3b deposition
The flow cytometry histograms in Figure 2A illustrate the 
binding of C5b-9 and iC3b to 500 and 750 nm PS-NPs, 
reflected in the increased fluorescence of gated PS-NPs after 1 
and 20 minutes’ incubation. Except for C5b- sC5b-9 binding 
to 500 nm PS-NPs, such increases were observed in four of 
seven pigs’ sera for both labels. Figure 2B shows that maxi-
mal changes compared to baseline were significant (P,0.05); 
nevertheless, the fact that positivity was not observed in 
all sera points to individual variation in C activation and 
deposition. The delay of maximal staining of iC3b vs C5b-9 
(1 vs 20 minutes) in individual pigs is consistent with the 
kinetics of the formation of these C-activation byproducts, 
the former testifying for C5b and hence C5a formation, while 
the appearance of iC3b provides evidence of opsonization. 
Interestingly, 750 nm PS-NPs displayed stronger expression 
of these C-activation markers than 500 nm NPs, a difference 
that returned in other experiments of this study. Of note, 200 
nm PS-NPs were not tested, as they were invisible to our flow 
cytometry instrument.
Western blot evidence for opsonization 
of Ps-NPs in pig serum
Immunochemical analysis of C3 following incubation with 
PS-NPs showed rapid time-dependent formation of bands 
below 60–70 kDa in case of 500 and 750 nm, but not 200 nm 
NPs. This observation indicates iC3b formation and its fur-
ther proteolytic fragmentation on .200 nm PS-NPs (framed 
in red on Figure 3). Based on human data,20,21 the larger frag-
ments can tentatively be identified as iC3b α’1 (Figure 3, 
upper red box) while the smaller fragments correspond to 
Figure 1 (A) Direct cryo-TeM imaging of polybead Ps-NPs and liposomes.
Notes: (A–D) NPs and liposomes of 200, 500, and 750 nm diameter, respectively. (E) surface hydrophobicity of Ps-NPs assessed by the adsorption of transmission electron 
microscopy, rose bengal in NPs. The x-axis is the sa and the y-axis percentage change of OD550, calculated thus: %OD550 = ODno particles - ODparticles/ODno particles. R
2 refers to 
logarithmic fitting. These data reveal fundamental differences between PS-NPs and liposomes, as well as other known therapeutic NPs.
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Figure 2 Flow cytometric analysis of terminal complex (c5b-9) and ic3b formation on Ps-NPs on a time course of minutes.
Notes: Following incubation with one representative (A) or seven (B) pig sera. (A) Fluorescence intensity of beads (500 and 750 nm) at baseline (0 minutes) and after 
incubation with serum for 1 and 20 minutes, followed by staining with anti-c9neo (ae11) and Pe labeled anti-mouse antibody, or by FITc labeled anti-ic3b (7c12); “20 
minutes + eDTa” indicates presence of 20 mM eDTa during incubation. (B) Means ± SD of fluorescence values (maximum and zero time point) of beads after incubation 
with the sera of seven pigs. Before incubation, 500 and 750 nm PS-NPs were mixed together at equal surface quantities and discriminated during flow cytometry analysis via 
their side scattering signals. Only basic fluorescent signals were observed at time 0, in EDTA-containing samples, and in those that were stained only with secondary antibody. 
*Statistically significant differences between 0-minute and maximum values, calculated by paired t-test.
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Figure 3 Proteolytic by products of C3 in pig serum following incubation with PS-NPs. The molecular weight markers and tentatively identified proteolytic fragments are 
shown on the left and right sides of the blot, respectively.
Notes: after sodium dodecyl sulfate polyacrylamide-gel electrophoresis of serum under reduced conditions, c3 fragments were stained with rabbit polyclonal anti-pig c3 
antibody produced by immunization with C3 peptide (aa23-300). Red boxes demarcate the cleavage products of porcine C3 that increase over time after the first sample 
at 2 min. These bands seem to correspond to human ic3b α’ fragment 1 (α’1) and 2 (α’2) in the upper (500 nm) and lower (750 nm) boxes, respectively, that may also 
include C3dg and/or C3d. The baseline (0 minute) was tested in a separate membrane and showed minor spontaneous proteolysis. Fragments were tentatively identified 
(right side of the blot, “PF”) on the basis of their relative electrophoretical mobility in human serum or plasma.20,21 Other details are described in the Materials and methods 
section.
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contribution of carPa to polystyrene NP effects in pigs
iC3b α’2 and/or C3dg and/or C3d (Figure 3, lower red box). 
Consistent with other findings in this study, the formation 
of α’2, C3dg and/or C3d was most pronounced on 750 nm 
PS-NPs. Since iC3b, C3dg and C3d are all known opsonins, 
these data provide evidence for PS-NP opsonization on a 
time scale of minutes.
complement activation by Ps-NPs 
in normal human sera: dose and time 
dependence and activation pathway
Figure 4 shows that spherical 500 and 750 nm PS-NPs caused 
significant rises in sC5b-9 relative to PBS control, while 
200 nm particles had only a minor, insignificant effect. The 
former data are in keeping with other studies on C activation 
by PS-NPs in human serum9,22 and are in sharp contrast with 
the lack of activation by the same PS-NPs in pig serum under 
similar conditions (inset in Figure 4).9
Since total SA was the same with all three NP types, the 
differences observed in sC5b-9 formation point to membrane 
curvature having an impact on C activation. Considering the 
surface requirement of C3-convertase assembly and hence 
launching of the terminal pathway, it is very likely that 
the flatter surface of larger particles played a role in their 
increased C activation.
Pathway of complement activation by 
Ps-NPs in human sera
Figure 5 shows the effects of 200, 500, and 750 nm PS-NPs 
(of equal total SA) on C3a, Bb, sC5b-9, and C4d levels 
following incubation with different normal human serum 
(n=3–5) for 45 minutes. Consistently with Figure 4, 500 and 
750 nm PS-NPs caused significant elevation sC5b-9, and C3a 
and Bb showed similar changes. On the other hand, C4d did 
not change. The latter observation, together with the signifi-
cant rise of Bb, indicates alternative pathway activation.
The expression of C activation as percentage of zymosan 
in Figure 5 allows yet another conclusion: that C activation 
by PS-NPs was relatively weak compared to the effect of 
zymosan, at least under the conditions studied. It was a 
maximum of 10%–40% of the strength of zymosan for C3a 
and Bb taken as end points, and even less, ,10%, with 
sC5b-9 readout. On the other hand, C4d increases were not 
significantly different from that caused by zymosan, which is 
in keeping with the fact that zymosan is primarily an alterna-
tive pathway activator.
complement activation by Ps-NPs 
in normal human sera: dose and time 
dependence
To understand C activation by PS-NPs in normal human 
serum further, we measured 500 nm PS-induced changes 
in C3a as a function of incubation time. Although the low 
values made it difficult to discern the initial kinetics of C 
activation, the linear regression line fitted on the data in 
Figure 6A suggests that C activation might have started 
instantly, within minutes. Figure 6B shows an experiment 
where we tested sC5b-9 formation as a function of 500 nm 
NP dose, expressed as multiples of 24.4 cm2/mL. The data 
suggested near-maximal effect at the latter dose in two of 
the three tested sera (donors 1 and 2). However, probably 
because of individual differences in C3-convertase and 
terminal-complex (C5b-9) formation, saturation was not 
reached in the remaining case (donor 3).
correlation between c activation by Ps-
NPs and pulmonary vasoactivity in pigs
The data presented thus far in pig and human sera pro-
vided evidence that C activation in blood may start within 
minutes after exposure to PS-NPs. This is consistent with 
the time course of pulmonary reaction in pigs, peaking at 
2–5 minutes; however, in the absence of a specific and fully 
effective C inhibitor, it does not prove causal relationship. To 
fill this gap of information, we injected pigs with different 
Figure 4 complement activation by different Ps-NPs in human sera expressed as a 
percentage of zymosan (0.3 mg/ml).
Notes: Particle numbers were adjusted to represent equal surface (72.5 cm2/ml 
serum) and NPs incubated with sera for 45 minutes at 37°c, followed by elIsa 
of sc5b-9. Values are means ± SD for five sera. P-values were determined by one-
way aNOVa, followed by Tukey’s multiple comparison. ***P,0.001 (500 nm vs 
PBs); **P,0.01 (750 nm vs PBs); *P,0.05 (500 vs 200). The inset is a reproduction 
(with permission) of Figure 2a in Wibroe et al.9 The Ps-NPs were differently 
shaped and referred to as spheres, rods, and disks. Their surface area was specified 
as ~145 cm2/ml. Values given as means ± sD (n=3). All values were significantly 
different from background, except spheres (open circles). Further details of both 
experiments are described in Wibroe et al.9
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PS-NPs to search for correlation between in vitro C activa-
tion and in vivo pulmonary reaction. Since flow cytometry 
and Western blotting were considered semiquantitative com-
pared to ELISA, and since the available porcine ELISAs of 
C byproducts gave earlier contradicting data,9 we used the 
human data shown in Figure 4 for this correlation. Specifically, 
we injected 200, 500, and 750 nm PS-NPs in pigs at equiva-
lent surface doses and monitored, among other parameters, 
the ensuing changes in PAP. These changes were quantified 
either as percentage change relative to baseline or area under 
Figure 5 responses of different c-activation markers to Ps-NP-induced c activation in normal human sera: dependence on NP size.
Notes: (A–D) rises in c3a, Bb, sc5b-9, and c4d, respectively, following incubation with 500 nm Ps-NPs (72.5 cm2/ml) for 45 minutes at 37°c. Means ± sD (n=5), except 
PBs (n=3–5). ***P,0.001, **P,0.01 relative to baseline, calculated by one-way aNOVa followed by Tukey’s multiple comparison.
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Figure 6 Time (A) and dose (B) dependence of c activation by 500 nm Ps-NPs in three different human sera, measured by the production of c3a and sc5b-9, respectively.
Notes: (A) Ps-NPs at 218.1 cm2/ml were incubated with different human sera for the times indicated; values represent means ± sD (N=3). linear regression line R2=0.7852, 
P,0.0001. (B) Multiples of 24.2 cm2/ml (72.7 and 218.1 cm2) 500 nm Ps-NPs were incubated with three human sera (different shades) for 45 minutes at 37°c.
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contribution of carPa to polystyrene NP effects in pigs
the curve, as specified for each experiment, and values were 
correlated with the sC5b-9 values shown in Figure 4, also 
expressed as percentage change relative to baseline.
Nevertheless, as a first step, we had to establish the 
dynamic range of PS-NP-induced pulmonary hypertension in 
pigs for 200, 500, and 750 nm PS-NPs, applying identical 
total NP SAs. As shown in Figure 7A, the smallest dose of 
200 nm NPs (5 ng/kg, blue line) did not cause any change in 
PAP, while identical surfaces of 500 (Figure 7B) and 750 nm 
(Figure 7C) PS-NPs led to massive pulmonary hypertension. 
These findings are consistent with the in vitro observations 
on C activation, opsonization, and iC3b formation caused by 
the same PS-NPs in Figures 2–4. Figure 7A–C also shows 
that ten- and 40-fold higher doses of all three NP types 
caused major increases in PAP response, and the dynamic 
window of the pulmonary hypertensive effect of PS-NPs 
was in a NP size-dependent subthreshold-dose range. The 
minimum effective (threshold) values were ,50 ng/kg for 
200 nm PS-NPs and ,13 and ,19 ng/kg for 500 and 750 
nm PS-NPs (Figure 7A–C).
The data in Figure 7 also illustrate the severe hemody-
namic derangement following IV injection of PS-NPs which 
Figure 7 real-time tracing of PaP in pigs.
Notes: Pigs injected with 200 (A), 500 (B), and 750 nm (C) PS-NPs at three equivalent surface doses, specified in the color coded insets as ng PS-NP/kg pig body weight. 
Representative curves in one of five pigs treated identically, whose maximal PAP values are summarized in the PAP column of Table 2. (D) correlation between c activation 
in human sera and pulmonary hypertensive effect of different Ps-NP types. Both variables given as percentage change, calculated by (Δmax - baseline/baseline × 100) - 100, 
where Δmax is the maximal sc5b-9 and PaP response at the peak of the reaction. Different symbols show different Ps-NP types; the mean and seM values are given in Table 2. 
The correlation is significant at two-tailed P=0.033 (Pearson’s r=0.9667).
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arises on similar time course as the opsonization of different-
size NPs in pig sera in vitro (Figures 2 and 3). In addition, they 
highlight that 500 and 750 nm PS-NPs caused massive pul-
monary hypertension at ,20 ng/kg, which is at least ten times 
lower than the minimally reactive liposome or zymosan doses 
causing similar reactions.1,23–26 Therefore, these NPs represent 
the most effective inducers of pulmonary hypertension in pigs 
among a broad variety of NPs tested to date.1,23–26
The parallelism between C activation by different-size 
PS-NPs in human sera (Figure 4) and their pulmonary 
reactivity in pigs (Figure 7) is apparent from the data in 
Table 2 and Figure 7D, correlating the maximal PAP rises 
after injection of equivalent surface doses of different PS-NP 
types in five pigs.
Plotting the mean PAP values against sC5b-9 (Figure 7D) 
followed by regression analysis indicated significant (P=0.03) 
correlation, which was remarkable considering that in vitro 
data were correlated with in vivo physiological changes in 
entirely different systems under entirely different condi-
tions. This correlation represents a major argument for the 
relevance of C activation in PS-NP-induced pulmonary 
changes in pigs. Figure 8 extends the findings on the particle-
size dependence of PS-NP-induced pulmonary hypertension 
of pigs inasmuch as it shows remarkable reproducibility of 
this size dependence (Figure 8A, top) and the fact that the 
systemic arterial pressure changes were relatively small or 
negligible (Figure 8A, bottom).
Figure 8B shows that increasing the minimally reac-
tive NP number tenfold led to increasing acceleration 
of pulmonary reaction to different-size NPs in the order 
200,500,750 nm. Furthermore, increasing the minimal 
dose 40-fold yielded maximal effect only with the largest 
(750 nm) PS-NPs, suggesting that in addition to total SA, 
surface features also play a role in C activation. In our case, C 
activation was proportional with particle diameter in the 
200–750 nm range, possibly because the efficiency of the 
buildup of C3/C5 convertases and opsonins were higher on 
flat than on curved surfaces.
Discussion
This study continued the exploration of the role of C activa-
tion in PS-NP-induced pulmonary hypertension in pigs to 
Table 2 Overlap between maximal PaP rises caused by equivalent 
Ps-NP surface doses in pigs with c activation by equivalent surface 
doses of same Ps-NPs in human sera
PS-NP diameter, 
nm
PAP (max %) sC5b-9 (max %)
Mean SEM n Mean SEM n
Baseline 0 5 0 5
200 48 24 5 116 48 5
500 95 16 5 412 157 5
750 90 7 5 310 108 5
Notes: entries are percentage change (means ± seM, n=5), calculated by (Δmax - 
baseline/baseline × 100) - 100, where Δmax is maximal sc5b-9 and PaP response 
at the peak of the reaction compared to baseline. Doses injected in pigs were 5, 
12.5, and 19 ng/kg for 200, 500, and 750 nm Ps-NPs, respectively. serum-incubation 
parameters are given in Figure 4.
Abbreviations: c, complement; PaP, pulmonary arterial pressure; Ps-NPs, poly-
styrene nano particles.
Figure 8 effect of NP size on PaP and saP.
Notes: (A) changes in pulmonary (upper panel) and saP (lower panel) following injection of the minimally reactive doses of Ps-NPs in pigs as percentage changes relative to baseline; 
means ± sD (n=3). The key for line colors (top on Panel a) is the same for PaP and saP. (B) relationship between pulmonary vascular effects of Ps-NPs and particle diameter (color-
coded) and NP number (dose ratio). Bars represent means ± sD (n=3). Dose ratio means 10 and 40-fold of the minimally effective dose of differently sized NP-Ps (Figure 7a–c).
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contribution of carPa to polystyrene NP effects in pigs
provide further information regarding the CARPA vs RPR 
theories.8,10 The importance of revisiting this issue lies in the 
clinical relevance of C being or not being involved in infusion 
reactions, since C-based predictive assays and C-inhibition-
based preventive measures are still open, largely unexplored 
options in combating these adverse immune reactions.27 
Inhibition of C activation as adjunct therapy against acute 
life-threatening immunoactivation is getting increasing 
recognition,28–30 so premature or unfounded exclusion of 
C activation as a key contributing mechanism of infusion 
reactions may be misleading in this field.
The original observations giving rise to questioning the 
role of C in the significant pulmonary hypertensive effect of 
500 nm spherical PS-NPs in pigs was the lack of C activa-
tion in hirudinized pig whole blood in vitro. On the other 
hand, aspheric PS-NPs (rods and disks) derived by a film-
stretching method did activate C in pig whole blood, yet they 
did not cause pulmonary reactions in vivo.9 On top of these 
controversial findings, all PS-NPs led to significant rises of 
sC5b-9 and C3bc in human whole blood.9 Keeping the goal 
of correlating in vitro C activation with in vivo pulmonary 
response without these inconsistencies, here, we used a sim-
pler approach: instead of shape modification, we used only 
spherical PS-NPs whose diameters were different, namely, 
200, 500, and 750 nm. Because spherical PS-NPs have been 
shown to bind to red blood cells,9 for these in vitro studies, 
we used sera, rather than whole blood.
The experimentally derived evidence in the present 
study seems more in support of the involvement than the 
irrelevance of C activation in PS-NP-induced HSRs in pigs. 
In particular, our demonstration of time-dependent formation 
of opsonic iC3b and its smaller, also opsonic fragments in 
pig serum incubated with PS-NPs, proceeding on the same 
minute scale that HSRs occur, provides multiple, coherent 
strong support to the idea that instant PS-NP-induced C 
activation in pig blood may contribute to the pulmonary 
reaction. The reason for the discrepancy between this and the 
previous study has not been clarified to date. As emphasized 
by many,10,31–34 the detection of C activation in animals in vivo 
may critically depend on methodology, and in vitro–in vivo 
extrapolations in this field have many potential pitfalls. It is 
notable in this regard that C activation by NPs is a dynamic, 
often reversible process that is influenced (in addition to the 
physicochemical properties of NPs and plasma factors) by 
the protein spectrum in the NP corona.35
As for the mechanism of C activation by PS-NPs, the 
present study indicated alternative-pathway C activation, at 
least in human serum. Whether or not this holds in pigs and 
other species as well remains to be established in the future. 
We also established a significant impact of NP size and thus 
surface geometry (curvature) on C activation, most likely 
related to the flatness of particle surfaces on which C proteins 
are deposited. Although we did not investigate, size-dependent 
aggregate formation36 may also play a role in C activation 
by PS-NPs, a possibility that requires further attention.
With regard to the RPR vs CARPA debate, since 
opsonization is a well-known trigger for enhanced phagocytic 
uptake,37–39 it is highly likely that it played a role in RPR, 
ie, “robust” uptake of PS-NPs by pulmonary intravascular 
macrophage cells.9 On this basis, the RPR theory is consis-
tent, rather than compete with the CARPA concept. These 
ideas can be reconciled by the “double-hit” hypothesis on 
simultaneous, double, or multiple activation of allergy-
mediating cells via different pathways.40,41 Nevertheless, the 
relative roles of different intracellular signaling channels, the 
complex relationship among anaphylatoxin effects, direct 
binding of NPs to a variety of pathogen-associated membrane 
receptors, C receptors, toll-like receptors, and many others, 
and phagocytosis and secretion of vasoactive mediators by 
allergy-mediating cells remain to be dissected. They may 
be more or less different for all NPs in different species for 
each individual case of HSRs.
In addressing the relevance of using PS-NPs to clarify the 
mechanism of nanomedicine-induced HSRs, the carboxylated 
PS-NPs studied here were not only highly hydrophobic but also 
more negatively charged than our control PEGylated nanolipo-
somes. Just like having high molar percentage of cholesterol in 
the bilayer of negatively charged liposomes,1,42 these features 
are known to accelerate C activation. On this basis, the use of 
PS-NPs as a nanomedicine-model system is questionable. As a 
matter of fact, on a weight basis, 500 and 750 nm PS-NPs have 
turned out to be the most potent inducers of cardiopulmonary 
distress in pigs studied for the past 20 years,18,43 most recently 
in minipigs for regulatory purposes.26 These NPs may thus 
join zymosan as a new positive standard for acute NP-induced 
HSRs that enables further dissection of their mechanism, in 
particular, the double-hit theory.
Finally, it should be pointed out that despite the worries 
about in vitro–in vivo projections, our results showing 
significant correlation between C activation by PS-NPs 
in human serum and their pulmonary hypertensive effect 
in pigs confirm the utility of in vitro C-activation assays 
in predicting the risk of NPs to cause severe infusion reac-
tions in hypersensitive individuals. As emphasized in recent 
regulatory documents, there is a great need for such predictive 
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The present study suggests the use of the porcine CARPA 
model1,17,18 along with in vitro C assays in human serum to 
evaluate both the general and individual risks of severe HSRs 
to nanomedicines.
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